Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people taking Wegovy notice a real reduction in hunger, but it rarely disappears entirely. Semaglutide works partly by slowing how quickly your stomach empties and by acting on appetite-regulating centres in the brain, which means meals feel filling sooner and the urge to eat between them tends to quieten. That said, hunger doesn't vanish overnight, it shifts — and for some people at certain doses it barely shifts at all, at least not yet. These are prescription-only medicines, and a prescriber assesses whether they're right for you before anything is dispensed.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Imagine it's three weeks in. Your pen arrived in an unbranded box, DPD tracking on your phone, and you've done your second injection. You expected hunger to disappear. Instead you're still thinking about lunch at 11am and wondering if something's wrong.
Nothing is. At the 0.25mg starting dose, semaglutide is doing a settling-in job, your system is adjusting to the medicine, and the appetite effects at that level are modest for most people. The full picture of how Wegovy works involves a gradual build: GLP-1 receptors in the hypothalamus and gut are being progressively activated, and that process takes the titration steps to really land.
Most people describe the change not as hunger vanishing but as a softening. The sharp, urgent feeling (the kind that makes you clock-watch until dinner) dulls. You still notice hunger, but it stops running the show. That's a meaningful shift, even if it doesn't feel dramatic at first.
According to NHS guidance on semaglutide, the most common early side effects are gastrointestinal (nausea, constipation, indigestion) and these can themselves suppress appetite temporarily. So in weeks one to four, reduced eating and reduced hunger are sometimes two different things happening for different reasons.
Here's the honest part: not everyone gets dramatic appetite suppression, even at 2.4mg maintenance. If you want a closer look at why some people find themselves hungry on Wegovy, the pattern is more common than most expect, with a portion of people on semaglutide reporting that physical stomach hunger remains present, while others find their relationship with food changes in subtler ways, less fixation, smaller portions feeling satisfying, less drive to finish a plate.
One reason is that hunger has layers. There's physiological hunger (low blood sugar, an empty stomach) and there's hedonic hunger, eating for reward, habit or emotion. Wegovy tends to dull the hedonic pull more noticeably for many people, which is why emotional eating patterns shift differently from straightforward appetite. If you're still eating out of boredom or stress rather than physical need, that's a separate thread worth addressing alongside treatment.
Dose is also a significant variable. The STEP 1 trial published in the New England Journal of Medicine found an average 15% body weight reduction at 68 weeks on the 2.4mg dose, results that reflect a population average, not every individual's experience. The titration ladder exists precisely because response varies.
If you're finding hunger persistent at a given dose, our page covering whether you still get hungry on Wegovy addresses this in more detail, though the right conversation about your own dosing is always with your prescriber, not the internet. Timing of the injection, protein intake, sleep and stress all interact with how appetite signals land.
Food choices matter more, not less, when appetite is reduced. A smaller stomach capacity means less room for nutrients, and the most common dietary problem on Wegovy isn't overeating, it's under-eating protein and skimping on vegetables because a handful of crackers satisfied the hunger signal.
Our Wegovy food guide goes into this properly, but the short version is: prioritise protein at each meal (it maintains muscle and extends the feeling of fullness), keep fibre coming in through vegetables and legumes, and stay well hydrated. GI side effects (nausea, constipation) are easier to manage on a diet built around whole foods than on ultra-processed ones, even if those are what you fancy when your appetite is low.
It's also worth knowing that if hunger returns sharply a few days before your next injection is due, that's a recognised pattern. Semaglutide's half-life means levels dip in the days before the next dose. Some people find adjusting when in the week they inject (always the same day, as instructed) helps maintain more even coverage, but any change to your schedule is a conversation for your prescriber, not something to adjust unilaterally.
If you're still working out how Wegovy fits your situation, the free consultation at nume starts that conversation properly. A real clinician reads your answers the same day, not automated software. For a broader view of what's available, our weight-loss treatment overview covers the options.
Curious about how the UK private cost compares? This page walks through Wegovy pricing context without any surprises.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.